FDA Approves Withdrawal of Obeticholic Acid Drug Applications from Market
Published Date: 11/24/2025
Notice
Summary
The FDA is officially pulling the approval for OCALIVA tablets (5 mg and 10 mg) and similar versions from three other companies, effective November 24, 2025. This affects patients, doctors, and pharmacies who use or sell these drugs, meaning they’ll need to find alternatives soon. The companies themselves asked for this change, so no surprise fees or penalties are involved.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
OCALIVA and Generics: Approvals Withdrawn
The FDA withdrew approval of the NDA for OCALIVA (obeticholic acid) tablets, 5 mg and 10 mg (NDA 207999), and three ANDAs for obeticholic acid tablets, 5 mg and 10 mg (ANDA 214862, ANDA 214980, ANDA 215017). Approval is withdrawn as of November 24, 2025, which affects patients, prescribers, and pharmacies connected to these products.
Postmarketing Trial Found Safety Concerns
FDA determined the postmarketing trial did not verify clinical benefit and found that OCALIVA-treated primary biliary cholangitis (PBC) patients with early-stage disease had an excess of liver transplants and deaths. FDA notified applicants and recommended voluntary withdrawal of approvals based on these findings.
Selling or Distributing These Tablets Becomes Illegal
After November 24, 2025, distributing OCALIVA or the listed obeticholic acid tablets into interstate commerce without an approved application is illegal and subject to regulatory action under sections 505(a) and 301(d) of the FD&C Act. Pharmacies, wholesalers, and other distributors should not distribute these products after that date.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13101 — Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Absorber
The FDA is officially classifying the medial knee implanted shock absorber as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative knee device faster and with confidence in its safety. The new classification is effective June 29, 2026, and could save time and money for makers and users alike.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-12906 — Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability
The FDA has officially ended emergency use for three COVID-19 test kits from BD, InBios, and Roche as of early 2026. This means these specific tests are no longer authorized for quick COVID-19 detection or diagnosis. If you or your organization used these tests, it’s time to switch to other approved options—no extra costs or penalties, just a smooth transition.
2026-12884 — Agency Information Collection Activities; Proposed Collection; Comment Request; Time and Extent Applications for Nonprescription Drug Products
The FDA wants your thoughts on how they collect info about nonprescription drug applications, especially about timing and usage. This affects drug makers and anyone interested in over-the-counter meds. You’ve got until August 25, 2026, to share your comments—no fees, just your voice helping shape the process!
Previous / Next Documents
Previous: 2025-20766 — Float Glass Products From China and Malaysia; Revised Schedule for the Subject Proceeding
The U.S. International Trade Commission is updating the timeline for its investigation into float glass products from China and Malaysia. This affects companies involved in importing or selling these glass products, with new deadlines for reports, hearings, and final decisions set between December 2025 and February 2026. The changes come after a government funding pause delayed the process, so everyone should get ready for the fresh schedule and upcoming money-impacting decisions.
Next: 2025-20768 — Tobacco Products Scientific Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments
The FDA is hosting a public online meeting on January 22, 2026, where experts will discuss tobacco product rules and give advice. Anyone interested can share their thoughts by January 21, 2026, through a public comment system. This meeting affects tobacco companies, public health groups, and anyone curious about tobacco safety and regulations.